Table 1.
Baseline demographic and clinical characteristics
| Galunisertib 160 mg/day plus sorafenib N = 7 |
Galunisertib 300 mg/day plus sorafenib N = 7 |
Total N = 14 |
|
|---|---|---|---|
| Age, years | |||
| Median (range) | 68 (50–79) | 67 (54–80) | 68 (50–80) |
| Gender | |||
| Female | 1 (14.3) | 1 (14.3) | 2 (14.3) |
| Male | 6 (85.7) | 6 (85.7) | 12 (85.7) |
| Weight, kg | |||
| Median (range) | 62 (44–80) | 65 (42–85) | 65 (42–85) |
| Pathological diagnosis | |||
| Hepatocellular carcinoma | 7 (100) | 7 (100) | 14 (100) |
| Disease etiology | |||
| Alcohol use | 1 (14.3) | 3 (42.9) | 4 (28.6) |
| Hepatitis B | 2 (28.6) | 2 (28.6) | 4 (28.6) |
| Hepatitis C | 3 (42.9) | 2 (28.6) | 5 (35.7) |
| Nonalcoholic fatty liver disease | 1 (14.3) | 0 | 1 (7.1) |
| ECOG PS | |||
| 0 | 6 (85.7) | 5 (71.4) | 11 (78.6) |
| 1 | 1 (14.3) | 2 (28.6) | 3 (21.4) |
| Child-Pugh Stage A | 7 (100) | 7 (100) | 14 (100) |
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status. Data are n (%) unless otherwise indicated